Metabolik sendromda ürik asit düzeyi ile nonalkolik yağlı karaciğer hastalığı arasındaki ilişki

Amaç. Bu çalışmanın amacı metabolik sendrom (MS) hastalarında non-alkolik yağlı karaciğerhastalığının (NAYKH) sıklığını ve serum ürik asit değeri ile arasındaki ilişkiyi araştırmaktır.Yöntem. Çalışmaya 26sı erkek ve 34ü kadın toplam 60 MS olgusu ile 21i erkek ve 21i kadıntoplam 42 sağlıklı birey alındı. On iki saatlik açlık sonrası alınan kan örneklerinde; açlık kanşekeri (AKŞ), trigliserid, yüksek dansiteli lipoprotein, düşük dansiteli lipoprotein (LDL), ürik asitdüzeyleri ve insülin değerlerine bakıldı. İnsülin direncini belirlemek için HOMA-IR formülükullanıldı. Karaciğer yağlanmasının derecesi ultrasonografik olarak değerlendirildi. Bulgular.Çalışmamızda MS grubundaki ürik asit düzeyleri, kontrol grubu olgularının ürik asitdüzeylerinden istatistiksel olarak anlamlı olacak şekilde yüksekti (p

The relation between serum uric acid levels and nonalcoholic fatty liver disease in metabolic syndrome.

Aim. The purpose of this study is to investigate the frequency of non-alcoholic fatty liver disease(NAFLD) in patients diagnosed as metabolic syndrome (MS) and also to find out its relation withserum uric acid levels. Methods. A total of 60 MS patients (26 male, 34 female) and 42 healthyindividuals (21 male, 21 female) were included in the study. After a fasting period of 12 hours,serum glucose, triglyceride, high density lipoprotein, low density lipoprotein, uric acid and insulinlevels were determined. HOMA-IR formula was used to determine insulin resistance.Ultrasonography was used in showing the grade of hepatosteatosis. Results. Mean serum uric acidlevel of the MS group was significantly higher than the control group in our study (p

PDF

___

1. Satman İ, Kocabay G. Diabet ve Karaciğer Yağlanması. Türkiye Klinikleri Tıp Bilimleri Dergisi 2006; 26: 1-12.
2. Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 2006; 55: 1293-301.
3. Yoo TW, Sung KC, Shin HS, Kim BJ, Kim BS, Kang JH, Lee MH, Park JR, Kim H, Rhee EJ, Lee WY, Kim SW, Ryu SH, Keum DG. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 2005; 69: 928-33.
4. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39.
5. Reaven GM. Banting lecture 1988. Role of İnsulin resistance in human disease. Diabetes 1988; 37: 1595-607
6. Klein BE, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care 2002; 25: 1790-4.
7. Ishizaka N, Ishizaka Y, Toda E, Nagai R, Yamakado M. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol 2005; 25: 1038-44.
8. Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol 2003; 18: 523-30.
9. Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Ann Epidemiol 1998; 8: 250-61.
10. Fenkçi S, Rota S, Sabir N, Akdağ B. Ultrasonographic and biochemical evaluation of visceral obesity in obese women with non-alcoholic fatty liver disease. Eur J Med Res. 2007; 12: 68-73.
11. Florkowski CM. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones. Am J Cardiovasc Drugs 2002; 2: 15-21.
12. Bunnag P, Chanprasertyothin S, Kongsuksai A, Ongphiphadhanakul B, Rajatanavin R, Puavilai G. Correlation between serum insulin and features of metabolic syndrome in Thais. J Med Assoc Thai 2000; 83: 783-9.
13. Mau MK, Grandinetti A, Arakaki RF, Chang HK, Kinney EK, Curb JD. The insulin resistance in native Hawaiians. Native Hawaiian Health Research (NHHR) Project. Diabetes Care 1997; 20: 1376-80.
14. Sonsuz A. Yağlı Karaciğer Hastalığı. Yurdakul İ, Şentürk H, Tuncer MM, Göksoy E. (editörler): Gastroenterolojide Klinik Yaklaşım. 1. baskı. İstanbul Deomed Medikal Yayıncılık; 2004: 171-80.
15. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic Fatty Liver, steatohepatitis and the metabolic syndrome. Hepatology 2003; 37: 917-23.
16. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, Ida K. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 722-8.
17. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005; 172: 899-905.
18. Akbar DH, Kawther AH. Non-alcoholic fatty liver disease and metabolic syndrome: what we know and what we dont know. Med Sci Monit 2006; 12: 23- 6.
19. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.
20. Tarantino G, Saldalamacchia G, Conca P, Arena A. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J Gastroenterol Hepatol 2007; 22: 293-303.
21. Lonardo A, Loria P, Leonardi F, Borsatti A, Neri P, Pulvirenti M, Verrone AM, Bagni A, Bertolotti M, Ganazzi D, Carulli N; POLI.ST.E.N.A. Study Group. Policentrica Steatosi Epatica Non Alcolica. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. Dig Liver Dis 2002; 34: 204-11.